HER2 Positive Gastric Cancer Market is expected to be valued at USD 1779.8 million by 2033, at a CAGR of 3.5%

HER2 Positive Gastric Cancer Market

The global HER2 Positive Gastric Cancer Market is currently valued at USD 1261.8 million in 2023, with a CAGR of 3.5% expected. Because of technological advancements in healthcare, the market is expected to reach USD 1779.8 million by 2033.

“Increased disease burden and pipeline candidate approval are likely to drive the growth of the HER2 positive market during the forecast period.”

The rising awareness about the symptoms and causes of gastric cancer will bring immense growth opportunities for the HER2-positive gastric cancer market.The rising company activities in conducting clinical trials for developing effective drugs for patients suffering from HER2 positive gastric cancer as well as increasing product launches and approvals are expected to fuel the market growth.

For instance, in January 2021, the U.S. FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers. Additionally, the increasing number of special designations for drugs in the pipeline is also expected to fuel the growth of the market.

North America dominates the HER 2 positive gastric cancer market due to the presence of key market players’ presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market’s growth in the region. The significant R&D investments in Europe abode well for market growth.

Key Takeaways from the Market Study

• As of 2023, the HER2 positive gastric cancer market was valued at US$ 1261.8 Million
• From 2023 to 2033, the HER2 positive gastric cancer industry is poised to grow at an 3.5% CAGR
• By 2033, the HER2 positive gastric cancer market is slated to reach a valuation of US$ 1779.8Million
• Based on therapy, the targeted therapy segment dominated the global market in 2023 with a revenue share of over 55.4%.
• China is poised to yield a CAGR of 3.2% with respect HER2 positive gastric cancer in 2033

“Technological advancement in healthcare and increase in the prevalence of gastric cancer is expected to radically transform the HER 2 positive gastric cancer market in the coming years,” comments an analyst at FMI.

Competitive Landscape

• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Ono Pharmaceutical Co. Ltd
• Hutchison Medipharma
• LintonPharm
• Shanghai Henlius Biotech
• Sanofi
• Pfizer
• Novartis AG

Manufacturers and players functional in the global HER 2 positive gastric cancer market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.

• In September 2022 -Shanghai Henlius Biotech, Inc announced a phase 1 clinical trial of the company’s HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanised monoclonal antibody(mAb) injection, has been completed in patients with HER2 overexpressing advanced solid tumours. The results of this study demonstrated the good safety and tolerability of HLX22.
• In January 2022 — LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that it has completed the enrollment of stage 1 of the global phase III trial (clinicaltrials.gov: NCT04222114). This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis (GCPC).

A Full Report Overview

Key Segments Covered in HER2 Positive Gastric Cancer Industry Survey

HER2 Positive Gastric Cancer Market by Therapy:

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy

HER2 Positive Gastric Cancer Market by Stage:

• Stage I
• Stage II
• Stage III
• Stage IV

HER2 Positive Gastric Cancer Market by End-User:

• Ambulatory surgery centres,
• Hospitals and Specialty clinics
• Others

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube